Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
They affect every aspect of what you are injecting
Lee, MD, MPH, a professor of pediatrics and communicable diseases at the University of Michigan School of Public Health, and colleagues, interest in GLP-1 receptor agonists have soared in the past decade, especially after the 2021 approval of semaglutide (Wegovy, Novo Nordisk) for weight management in adults
[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
Cardiovascular Risk Reduction The SELECT trial showed semaglutide reduces the risk of major cardiovascular events (heart attack, stroke) by 20% in overweight or obese adults with established cardiovascular disease
